Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy 9 Meters Biopharma stock in Canada

Own 9 Meters Biopharma shares in just a few minutes.

9 Meters Biopharma is a business based in the US. 9 Meters Biopharma stocks (INNT.US) are listed on the NASDAQ and all prices are listed in US Dollars. 9 Meters Biopharma employs 8 staff and has a market cap (total outstanding stock value) of $23.1 million.

How to buy 9 Meters Biopharma stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: INNT in this case.
  5. Research 9 Meters Biopharma stocks. The platform should provide the latest information available.
  6. Buy your 9 Meters Biopharma stocks. It's that simple.

Is it a good time to buy 9 Meters Biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

9 Meters Biopharma stock price

Use our graph to track the performance of INNT stocks over time.

9 Meters Biopharma stocks at a glance

Information last updated 2021-01-23.
Latest market close$N/A
52-week range$0.6622 - $0.87
50-day moving average $0.7269
200-day moving average $0.6081
Wall St. target price$10
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.491

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Wealthsimple Trade
Stocks, ETFs
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $150.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
BMO InvestorLine
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$9.95 + $1.25 per options contract
$0 if conditions met, otherwise $25/quarter
$0 - $9.95
Buy and sell a select group of Canada’s most popular ETFs without paying commissions.

An easy-to-use online trading platform with access to research, tools, and the option to access InvestorLine adviceDirect for additional professional support.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$9.95 + $1 per contract
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Get up to 50 free trades. Be one of the first 100 new Qtrade clients to use the promo code 50FREETRADES and deposit a minimum of $10,000 (or top up to $15,000 to get $150 transfer fees waived). Valid until September 30, 2021.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

9 Meters Biopharma financials

Gross profit TTM USD$0
Return on assets TTM -193.21%
Return on equity TTM 0%
Profit margin 0%
Book value $0.14
Market capitalisation USD$23.1 million

TTM: trailing 12 months

How to short and sell 9 Meters Biopharma stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "INNT.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 2.2 million 9 Meters Biopharma stocks held short by investors – that's known as 9 Meters Biopharma's "short interest". This figure is 1.7% down from 2.2 million last month.

There are a few different ways that this level of interest in shorting 9 Meters Biopharma stocks can be evaluated.

9 Meters Biopharma's "short interest ratio" (SIR)

9 Meters Biopharma's "short interest ratio" (SIR) is the quantity of 9 Meters Biopharma stocks currently shorted divided by the average quantity of 9 Meters Biopharma stocks traded daily (recently around 519741.86602871). 9 Meters Biopharma's SIR currently stands at 4.18. In other words for every 100,000 9 Meters Biopharma stocks traded daily on the market, roughly 4180 stocks are currently held short.

However 9 Meters Biopharma's short interest can also be evaluated against the total number of 9 Meters Biopharma stocks, or, against the total number of tradable 9 Meters Biopharma stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case 9 Meters Biopharma's short interest could be expressed as 0.03% of the outstanding stocks (for every 100,000 9 Meters Biopharma stocks in existence, roughly 30 stocks are currently held short) or 0.027% of the tradable stocks (for every 100,000 tradable 9 Meters Biopharma stocks, roughly 27 stocks are currently held short).

Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against 9 Meters Biopharma.

Find out more about how you can short 9 Meters Biopharma stock.

9 Meters Biopharma stock dividends

We're not expecting 9 Meters Biopharma to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

Have 9 Meters Biopharma stocks ever split?

9 Meters Biopharma stocks were split on a 1:10 basis on 1 February 2018. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your 9 Meters Biopharma stocks – just the quantity. However, indirectly, the new 900% higher stock price could have impacted the market appetite for 9 Meters Biopharma stocks which in turn could have impacted 9 Meters Biopharma's stock price.

9 Meters Biopharma stock price volatility

Over the last 12 months, 9 Meters Biopharma's stocks have ranged in value from as little as $0.6622 up to $0.87. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while 9 Meters Biopharma's is -0.5435. This would suggest that 9 Meters Biopharma's stocks have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, 9 Meters Biopharma has bucked the trend.

9 Meters Biopharma overview

9 Meters Biopharma, Inc. operates as a rare, orphan, and unmet needs-focused GI company. The company is advancing its drug candidates for short bowel syndrome and celiac disease. Its product candidates include NM-002, a proprietary long-acting GLP-1 agonist into Phase 2 trial for short bowel syndrome; and larazotide, a Phase 3 tight junction regulator being evaluated for patient-reported symptom improvement in non-responsive celiac disease. The company's pipeline products also includes NM-004, an oral gut restricted immunomodulator and NM-003, a long-acting GLP-2 analogue, both of which are under orphan indication selection. 9 Meters Biopharma, Inc. owns global rights to its products. The company is based in Raleigh, North Carolina.

9 Meters Biopharma in the news

There are no recent company news

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

Go to site